Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...
Reexamination Certificate
2007-04-17
2007-04-17
Mendez, Manuel (Department: 3763)
Surgery
Means for introducing or removing material from body for...
Treating material introduced into or removed from body...
Reexamination Certificate
active
10089224
ABSTRACT:
This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and animals. An axial collapse prevention element (2) to prevent excessive axial deflection of the dose administrator (1) or a dose-location coordinate indicator (3) to facilitate the delivery of a dose to the desired target location may be coupled to the dose administrator (1). An intranasal probe (4) having a force dissemination contact surface (7) may be responsive to a first end of the dose administrator (1). The dose may be delivered from a conformable dose sequestration element (10) through an aperture which penetrates the dose delivery aperture element (5) and the dose may be caused to stream by coupling a stream delivery element (6) to the dose delivery aperture element (5). The force application element (12) which acts upon the dose may be separated from the dose by a fluid dose propellent (13). While the invention may be used for numerous applications, it specifically addresses the difficulties of delivering cold-adapted live equine influenza viruses intranasally to equids.
REFERENCES:
patent: 3927208 (1975-12-01), Zygraich et al.
patent: 3950512 (1976-04-01), Emery et al.
patent: 3953592 (1976-04-01), Peetermans
patent: 3962422 (1976-06-01), Parks
patent: 4009258 (1977-02-01), Kilbourne
patent: 4029763 (1977-06-01), Kilbourne
patent: 4053583 (1977-10-01), Gits et al.
patent: 4110427 (1978-08-01), Kalat
patent: 4110433 (1978-08-01), Purdy, III
patent: 4132775 (1979-01-01), Volenec et al.
patent: 4136168 (1979-01-01), Fontanges
patent: 4195076 (1980-03-01), Fontanges
patent: 4512972 (1985-04-01), Schmidt-Rappin
patent: 4554158 (1985-11-01), Russell
patent: 4554159 (1985-11-01), Roizman et al.
patent: 4613500 (1986-09-01), Sukuki et al.
patent: 4683137 (1987-07-01), Coggins et al.
patent: 4693893 (1987-09-01), Campbell
patent: 4767416 (1988-08-01), Wolf et al.
patent: 4800078 (1989-01-01), Prince et al.
patent: 4923448 (1990-05-01), Ennis, III
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5026825 (1991-06-01), Grebow et al.
patent: 5158761 (1992-10-01), Kamishita et al.
patent: 5215739 (1993-06-01), Kamishita et al.
patent: 5250298 (1993-10-01), Gelb, Jr.
patent: 5284132 (1994-02-01), Geier
patent: 5289818 (1994-03-01), Citterio et al.
patent: 5331954 (1994-07-01), Rex et al.
patent: 5427782 (1995-06-01), Compans et al.
patent: 5601077 (1997-02-01), Imbert
patent: 5702362 (1997-12-01), Herold et al.
patent: 5720762 (1998-02-01), Bass
patent: 5843451 (1998-12-01), Compans et al.
patent: 6382204 (2002-05-01), Jansen et al.
patent: 6398774 (2002-06-01), Penner et al.
Anderson, E., et al., “Evaluation of a Cold-Adapted Influenza B/Texas/84 Reasserting Virus (CRB-87) Vaccine in Young Children”, Journal of Clinical Microbiology, Sep. 1992, p. 2230-2234.
Belshe, R., et al., “Immunization of Infants and Young Children with Live Attenuated Trivalent Cold-Recombinant Influenza A H1N1, H3N2, and B Vaccine”, The Journal of Infectious Diseases, 1992, p. 727-732.
Brown, A. and Slusser, J., “Propellant-driven Aerosols of Functional Proteins as Potential Therapeutic Agents in the Respiratory Tract”, Immunopharmacology, 28, 1994, p. 241-257.
Chanock, Robert M., et al, “Viral Immunology and Immunopathology”, Current Approaches to Viral Immunoprophylaxis, Academic Press, New York, 1975, p. 291-316.
Chien, Y.W., et al., “Nasal Systemic Drug Delivery”, Anatomy and Physiology of the Nose, Chapter 1, p. 1-26, 1989.
Dolovich, M., “Physical Principles Underlying Aerosol Therapy”, Journal of Aerosol Medicine, vol. 2, No. 2, 1989, p. 171-186.
Exhibit A, Wolfe Tory Medical, Inc., 79 West 4500 South, Salt Lake City, Utah 84107, Date received 1999.
Exhibit B, Fort Dodge Animal Health, Overland Park, Kansas, Date received 1998.
Exhibit C, Pfizer Animal Health, 601 West Cornhusker Highway, Lincoln Nebraska, Date received 1999.
Exhibit D, Trade Secret/Confidential Information.
Genesis Industries, Inc. brochure, “Select Innovative Versatile Quality delivery Systems and Syringe Components”, 1995, four pages.
Haneberg, B., et al, “Intranasal Administration of Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans, Infection and Immunity”, 66(4), p. 1334-1341, Apr. 1998.
Hannant, D. and Mumford, J., “Cell Mediated Immune Responses in Ponies Following Infection with Equine Influenza Virus (H3N8): the Influence of Induction Culture Conditions on the Properties of Cytotoxic Effector Cells”, Veterinary Immunology and Immunopathology, 21, 1989, p. 327-337.
Hannant, D., et al., “Duration of Circulating Antibody and Immunity Following Infection with Equine Influenza Virus”, The Veterinary Record, Feb. 6, 1988, two pages.
Henry, R.J., et al, “A pharmacokinetic Study of Midazolan in Dogs: Nasal Drop Versus Atomizer Administration”, Journal of the American Academy of Pediatric Dentistry, 20:5, p. 321-326, 1998.
Heska brochure, “Finally, A Vaccine Proven To Protect Against Equine Influenza” 10 Pages.
Hoffert, S., “Biotech Innovations Aim to Conquer Influenza Virus”, The Scientist, Mar. 2, 1998, p. 1 and 6.
Holmes, D., et al., “Live Temperature Sensitive Equine-2 Influenza A Virus Vaccine: Production and Efficiency in Experimental Ponies”, Equine Infectious Diseases VI, 1992 p. 253-258.
Jing-Quing, W., et al.,“An Experimental Study on Nasal Absorption of Gentamycin in Dogs”, Chinese Medical Journal, 107(3), p. 219-221, 1994.
Keitel, W., et al., “Trivalent Attenuated Cold-Adapted Influenza Virus Vaccine: Reduced Viral Shedding and Serum Antibody Responses in Susceptible Adults”, The Journal of Infectious Diseases, 1993, p. 305-311.
Klaus-Dieter-Budras, “Anatomy of the Horse, an Illustrated Text”, 2nd Edition, Mosby-Wolfe, London, 1994.
Louon, A., et al., “Sedation with Nasal Ketamine and Midazolam for Cryotherapy in Retinopathy of Prematurity”, British Journal of Ophthalmology, 77(8), p. 529-530, 1993.
Maassab, H.F., “Biologic and Immunologic Characteristics of Cold-Adapted Influenza Virus”, Journal of Immunology 102, No. 3, p. 728-732, 1969.
Maassab, H.F., et al, “Development and Characterization of Cold-Adapted Viruses for Use As Live Virus Vaccines”, Vaccine Department of Epidemiology, School of Public Health, The University of Michigan vol. 3, 1985.
Mumford, et al, “Serological Methods for Identification of Slowly-Growing Herpes viruses Isolated from the Respiratory Tract of Horses”, Equine Infectious Disease IV, The Journal of Equine Medicine and Surgery, Supplement No. 1, 1978, p. 49-52.
Mumford, et al, “WHO/OIE Meeting: Consultation on Newly Emerging Strains of Equine Influenza”, Vaccine 11, p. 1172-1174, 1993.
Mumford, et al, “Studies on Picornaviruses Isolated from the Respiratory Tract of Horses”, Equine Infectious Disease IV, The Journal of Equine Medicine and Surgery, Supplement No. 1, 1978, p. 421-429.
Nelson, K., et al., “Local and Systemic Isotope-Specific Antibody Responses to Equine Influenza Virus Infection Versus Conventional Vaccination”, Vaccine 1998, vol. 16, No. 13, pp. 1306-1313.
Newman, S.P., et al, “CHEST, In Vitro Comparison of DeVilbiss Jet and Ultrasonic Nebulizers”, 1987, 92: 991-994.
Nott, M.R., et al., “Topical Anesthesia for the Insertion of Nasogastric Tubes”, European Journal of Anesthesiology, 12(3), 1995.
PCT Application, PCT/US00/26,870, entitled, “Intranasal Delivery System”, filed Sep. 29, 2000.
Penner, et al., 37 Veterinary Concepts® catalog, Oct. 9, 1996, 116 pages.
Ralley, F.E., “Intranasal Opiate
Penner Steven J.
Sebring Randal W.
CR Miles P.C.
Heska Corporation
Mendez Manuel
Miles Craig R.
LandOfFree
Intranasal delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intranasal delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intranasal delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797420